Intellia vs Beam vs Prime Medicine: Next-Gen Gene Editing Stocks Compared

Three Technologies, Three Bets on the Future of Medicine

The gene editing sector is no longer a monolith. In 2023, the FDA's approval of Casgevy proved that CRISPR-Cas9 could deliver approved therapies. But the next wave of gene editing companies is not building on the same technology — they are building on fundamentally different molecular platforms, each with distinct scientific advantages, clinical risk profiles, and commercial trajectories.

Intellia Therapeutics (NASDAQ: NTLA) is betting that in vivo CRISPR-Cas9, delivered directly into the body, will dominate genetic medicine. Beam Therapeutics (NASDAQ: BEAM) believes base editing — precise single-letter DNA corrections without cutting the double helix — offers a safer, more controllable approach. Prime Medicine (NASDAQ: PRME) is wagering on prime editing, the most versatile editing technology ever developed, capable of making virtually any targeted DNA change.

For investors, the question is not which technology is "best" in the abstract. It is which company, at its current valuation and stage of development, offers the most compelling risk-reward profile. This article breaks down all three across technology, pipeline, financials, and investment thesis — and makes the case for which stock fits different portfolio strategies.

Disclaimer: This article is for educational and informational purposes only and does not constitute financial or investment advice. Gene editing stocks are highly volatile and carry significant binary risk. Always consult a qualified financial advisor before making investment decisions.

Side-by-Side Comparison

Metric	Intellia (NTLA)	Beam (BEAM)	Prime Medicine (PRME)
Market Cap	~$1.5B	~$2.8B	~$600M
Stock Price (Mar 2026)	~$14	~$28	~$6
52-Week Range	$8.50 – $28.00	$18.00 – $42.00	$3.20 – $11.50
Cash & Equivalents	~$700M	~$1.1B	~$350M
Cash Runway	Into 2028	Into 2029	Into 2028
Revenue (TTM)	Minimal (collaboration)	~$45M (collaboration)	Pre-revenue
Core Technology	CRISPR-Cas9 (in vivo)	Base editing (ABE/CBE)	Prime editing
Lead Program	Lonvo-z (NTLA-2001), ATTR	BEAM-101, SCD	PM359, CDKL5 deficiency
Most Advanced Phase	Phase 3 complete	BLA-track (Phase 1/2)	Phase 1/2
Delivery Platform	Proprietary LNP	LNP + ex vivo	LNP + AAV
Key Pharma Partner	Regeneron ($250M+)	Pfizer ($300M+), Apellis ($500M)	None announced
Employees (approx.)	~550	~480	~300

Intellia Therapeutics: The In Vivo CRISPR Pioneer

The Technology

Intellia's core platform is in vivo CRISPR-Cas9 gene editing — delivering lipid nanoparticles loaded with CRISPR components directly into the bloodstream to edit genes inside the body. This is a fundamentally different model from the ex vivo approach used by Casgevy, which requires extracting a patient's cells, editing them in a laboratory, and reinfusing them after myeloablative conditioning.

The in vivo approach offers a transformative advantage: scalability. An ex vivo gene therapy requires weeks of individualized manufacturing for every patient. An in vivo therapy is a single intravenous infusion — conceptually closer to a drug than a procedure. If Intellia's approach works, it could bring the cost and complexity of gene editing therapy closer to that of a biologic drug than a bone marrow transplant.

Intellia's proprietary LNP delivery system is optimized for liver targeting, which is why the company's pipeline is concentrated on liver-expressed diseases. The company co-developed its foundational CRISPR-Cas9 technology with Jennifer Doudna and holds key intellectual property through its license from the University of California.

The Pipeline

Intellia's lead program, lonvo-z (nexiguran ziclumeran, formerly NTLA-2001), targets transthyretin amyloidosis (ATTR), a progressive disease caused by misfolded transthyretin protein. A single IV infusion delivers CRISPR-Cas9 to hepatocytes, where it disrupts the TTR gene and stops production of the toxic protein.

The clinical data have been striking. In the Phase 3 study (completed in late 2025), lonvo-z demonstrated a mean serum TTR reduction exceeding 90% sustained through 24 months, with corresponding improvements in neuropathy and cardiomyopathy endpoints. If approved, lonvo-z would be the first in vivo CRISPR therapy to reach the market — a milestone comparable to Casgevy's ex vivo approval in terms of industry significance.

Beyond lonvo-z, Intellia's pipeline includes:

• NTLA-2002 — targeting hereditary angioedema (HAE) by editing the KLKB1 gene in the liver; Phase 2 data showed elimination of angioedema attacks in most patients
• NTLA-3001 — a gene insertion program for alpha-1 antitrypsin deficiency (AATD), using CRISPR to insert a functional SERPINA1 gene into hepatocytes
• Collaboration programs with Regeneron — including in vivo editing approaches for hemophilia A and B, and additional undisclosed targets

Financial Snapshot

Intellia's market capitalization of approximately $1.5 billion (as of March 2026) represents a significant discount from its 2021 peak above $10 billion. The company has approximately $700 million in cash and equivalents, providing runway into 2028 without additional fundraising. Revenue is minimal, consisting primarily of collaboration income from the Regeneron partnership (initially a $250 million upfront deal signed in 2024). The company's burn rate runs approximately $400 million annually, reflecting ongoing pivotal trials and pipeline expansion.

Wall Street analysts maintain a consensus price target in the $25–$35 range, implying roughly 80–150% upside from current levels (per FactSet and Bloomberg consensus data as of early March 2026). The wide range reflects genuine uncertainty about the regulatory path and commercial potential for lonvo-z.

Investment Thesis

The bull case for Intellia rests on a single, powerful argument: lonvo-z could be the first in vivo CRISPR therapy approved anywhere in the world, and that milestone would validate the entire in vivo editing platform. If lonvo-z reaches the market, Intellia's proprietary LNP delivery system and liver-targeting expertise become platform assets applicable across dozens of liver-expressed diseases. The ATTR market alone is estimated at $5–8 billion annually (based on current sales of tafamidis and other therapies), and a one-time curative treatment could command a significant share.

The bear case: Intellia's stock has already been beaten down by sector-wide biotech malaise, and the company has limited revenue diversification. If lonvo-z encounters a regulatory delay, a safety signal, or an unexpectedly competitive landscape from silencer therapies like eplontersen (Ionis/AstraZeneca), the stock could remain range-bound for another 12–18 months. Additionally, in vivo CRISPR is permanent and irreversible — any long-term safety concern could be devastating.

Michael Yee, an analyst at Jefferies, noted in a February 2026 research note: "Intellia is a binary event stock at this point. The lonvo-z BLA filing is the single most important catalyst in next-gen gene editing. If the filing goes smoothly, NTLA re-rates substantially. If there is a CRL or delay, the stock has limited downside protection."

Beam Therapeutics: Clinical Genetic Correction at Scale

The Technology

Beam Therapeutics is built on base editing, a technology developed by David Liu at the Broad Institute and Harvard University. Base editors use a modified Cas9 protein (which nicks one strand of DNA rather than cutting both) fused to a deaminase enzyme that chemically converts one DNA base to another — for example, changing a cytosine (C) to a thymine (T), or an adenine (A) to a guanine (G). This allows precise correction of point mutations without creating double-strand breaks.

The significance of avoiding double-strand breaks cannot be overstated. When CRISPR-Cas9 cuts both strands of DNA, the cell's repair machinery can introduce unintended insertions or deletions (indels), large deletions, or even chromosomal rearrangements. These are low-frequency events, but in a therapeutic context where billions of cells are edited, even low-frequency adverse outcomes matter. Base editing sidesteps this problem entirely, offering what many scientists consider a safer editing profile for clinical applications.

Beam holds exclusive licenses to adenine base editors (ABEs) and cytosine base editors (CBEs) for therapeutic applications, giving it a broad intellectual property moat across the base editing landscape.

The Pipeline

Beam's lead clinical program, BEAM-101, targets sickle cell disease by making a single A-to-G base change in the HBG1/HBG2 promoter region, which reactivates fetal hemoglobin (HbF) production. This is a similar therapeutic strategy to Casgevy — boosting fetal hemoglobin to compensate for defective adult hemoglobin — but executed through precise base conversion rather than CRISPR-mediated gene disruption.

The clinical data from the BEACON trial have been compelling. As of the most recent update in late 2025, BEAM-101 demonstrated fetal hemoglobin levels exceeding 40% in treated patients, with complete elimination of vaso-occlusive crises in all evaluable patients followed for more than 6 months. Crucially, no chromosomal abnormalities or concerning off-target edits were detected in extensive genomic safety analyses. These results have put BEAM-101 on a BLA (Biologics License Application) track, with a potential filing in late 2026 or early 2027.

Additional pipeline programs include:

• BEAM-302 — targeting alpha-1 antitrypsin deficiency (AATD) via in vivo base editing in the liver; Phase 1 initiated
• BEAM-301 — targeting glycogen storage disease type 1a (GSD1a); preclinical
• Multiplex base-edited CAR-T programs — using simultaneous base edits to create next-generation allogeneic CAR-T cells with enhanced persistence and reduced graft-versus-host risk

Beam's pharma partnerships add significant financial and strategic weight. The Pfizer collaboration (initiated in 2022, valued at over $300 million including upfront and near-term milestones) covers in vivo base editing for liver diseases. The Apellis partnership (announced in 2025, worth up to $500 million) focuses on complement-mediated diseases using base editing to modulate complement pathway genes. These deals validate Beam's platform and provide non-dilutive capital.

Financial Snapshot

Beam's market capitalization of approximately $2.8 billion makes it the largest of the three companies in this comparison. The company holds approximately $1.1 billion in cash and equivalents, providing runway well into 2029 — the longest runway of the three. Collaboration revenue from Pfizer and Apellis contributes approximately $45 million annually in recognized revenue. The company's burn rate is approximately $350–400 million per year.

Analyst consensus (per Bloomberg) places the price target for BEAM shares in the $38–$55 range, with bulls like Citi analyst Mohit Bansal arguing that the BEAM-101 BLA pathway alone justifies a $45+ target: "Beam is the closest to delivering clinical proof that base editing is not just theoretically superior to CRISPR cutting, but clinically superior in safety and predictability."

Investment Thesis

The bull case for Beam centers on platform validation and diversification. BEAM-101's BLA-track clinical data suggest that base editing can match or exceed the efficacy of CRISPR-Cas9 cutting for sickle cell disease while offering a cleaner safety profile. If BEAM-101 is approved, it would be the first approved base editing therapy — a milestone that validates the entire technology class. Meanwhile, the Pfizer and Apellis deals provide revenue visibility and reduce the need for dilutive capital raises.

The bear case: Beam's $2.8 billion market cap already prices in meaningful clinical success. The sickle cell disease market is competitive (Casgevy, Lyfgenia, and other emerging therapies), and BEAM-101's manufacturing process is still ex vivo, meaning it shares some of the scalability challenges that limit Casgevy's commercial uptake. Additionally, base editing is limited to the four transition mutations (C-to-T, A-to-G, and their complements) — it cannot make all types of DNA changes, which constrains the addressable mutation landscape compared to prime editing.

Geoffrey Porges at Leerink Partners has characterized Beam as "the quality play in next-gen editing — lower downside risk, but the premium valuation means the stock needs multiple pipeline wins to deliver outsized returns."

Prime Medicine: The Most Versatile Editor, the Earliest Stage

The Technology

Prime Medicine is commercializing prime editing, arguably the most significant advance in genome editing since CRISPR-Cas9 itself. Invented by David Liu and Andrew Anzalone at the Broad Institute (published in Nature in October 2019), prime editing uses a reverse transcriptase fused to a Cas9 nickase, guided by a prime editing guide RNA (pegRNA) that contains both the target sequence and the desired edit.

The result is a molecular "search-and-replace" tool that can make all 12 types of point mutations, small insertions (up to ~50 base pairs), small deletions, and combinations thereof — all without double-strand breaks and without requiring a separate donor DNA template. In terms of theoretical versatility, prime editing can address approximately 89% of known pathogenic human mutations listed in the ClinVar database, compared to roughly 30% for base editing and a more limited (though still meaningful) set for CRISPR-Cas9 gene disruption.

The tradeoff is complexity. Prime editors are larger molecular constructs than Cas9 or base editors, making delivery more challenging. Editing efficiency has historically been lower than CRISPR-Cas9 cutting, though Prime Medicine's proprietary engineering (including optimized pegRNA designs and improved prime editor proteins) has significantly closed this gap.

The Pipeline

Prime Medicine's lead program, PM359, targets CDKL5 deficiency disorder (CDD), a rare and severe neurological condition caused by mutations in the CDKL5 gene. The program generated significant attention in late 2025 when results published in the New England Journal of Medicine demonstrated 83% correction efficiency in patient-derived cells using prime editing — a landmark result that validated the technology's clinical potential.

The NEJM publication was a pivotal moment for the prime editing field. An 83% correction rate without double-strand breaks, achieved in disease-relevant cell types, demonstrated that prime editing had moved from a laboratory tool to a potential therapeutic modality. The paper was accompanied by an editorial describing prime editing as "the most precise genome editing tool available for human therapeutics."

More recently, Prime Medicine has been pivoting its pipeline strategy toward liver diseases, where LNP-mediated delivery to hepatocytes is more established. This strategic shift, announced in early 2026, reflects a pragmatic recognition that liver-directed programs have a clearer regulatory and delivery path than CNS-directed programs. New liver-focused programs targeting metabolic diseases are expected to enter IND-enabling studies in 2026.

Additional pipeline programs include:

• PM359 (CDD) — Phase 1/2 clinical development; AAV-delivered prime editing to the CNS
• Liver disease programs — multiple undisclosed targets using LNP-delivered prime editing; preclinical
• Duchenne muscular dystrophy (DMD) — preclinical prime editing approach to correct exon-skipping mutations

Financial Snapshot

Prime Medicine's market capitalization of approximately $600 million makes it the smallest and most speculative of the three companies. The company has approximately $350 million in cash (bolstered by a secondary offering in late 2025), providing runway into 2028. Prime Medicine is pre-revenue with no active pharma partnerships generating collaboration income. The annual burn rate is approximately $150–180 million, reflecting its earlier stage and smaller workforce.

Analyst coverage is thinner than for Intellia or Beam. The consensus price target among covering analysts is in the $12–$18 range (per FactSet), implying significant upside from the current ~$6 share price. However, only 4–5 analysts actively cover the stock, and coverage tends to be from specialist biotech shops rather than major banks. Analyst Tyler Van Buren at Cowen noted in a January 2026 initiation report: "Prime Medicine is the highest-upside, highest-risk name in our gene editing coverage. The technology is extraordinary, but the company needs to demonstrate in vivo delivery efficiency in humans to unlock the platform's potential."

Investment Thesis

The bull case for Prime Medicine is asymmetric upside. At a $600 million market cap, the stock prices in very little success. If prime editing delivers on even a fraction of its theoretical promise, the company could be worth multiples of its current valuation. The NEJM-published 83% correction data demonstrate that the technology works. The pivot to liver diseases aligns the delivery strategy with the most proven in vivo pathway. And because prime editing can address the broadest range of mutations, it has the largest theoretical total addressable market of any editing technology.

The bear case: Prime Medicine is genuinely early-stage. No prime editing therapy has advanced beyond Phase 1/2. Delivery efficiency in vivo remains the critical unknown — laboratory correction rates in patient-derived cells do not necessarily translate to therapeutic correction rates in human organs. The company has no pharma partnerships providing financial validation or non-dilutive capital. And at a $150–180 million annual burn, the $350 million cash position, while adequate, leaves limited margin for error if clinical timelines slip.

Historical Stock Performance

All three stocks have experienced the broader biotech downturn that began in late 2021 and has only partially reversed.

Metric	NTLA	BEAM	PRME
IPO / Listing Year	2016	2020	2022
All-Time High	~$202 (Aug 2021)	~$138 (Feb 2021)	~$28 (Nov 2022)
Current Price (Mar 2026)	~$14	~$28	~$6
Decline from ATH	~93%	~80%	~79%
12-Month Performance	-18%	+12%	-22%
YTD 2026	-5%	+8%	-10%

Beam has been the relative outperformer over the past 12 months, benefiting from strong BEAM-101 clinical data and the Apellis partnership announcement. Intellia has been range-bound as investors await clarity on the lonvo-z BLA filing timeline. Prime Medicine has underperformed as the market digests the pipeline pivot and assigns a higher discount rate to early-stage programs.

Analyst Price Targets and Consensus Ratings

	NTLA	BEAM	PRME
Consensus Rating	Overweight	Buy	Outperform
Median Price Target	$28	$45	$14
Bull Case Target	$55	$70	$25
Bear Case Target	$10	$20	$4
Number of Covering Analysts	14	12	5
% Buy/Overweight	71%	83%	80%

Sources: Bloomberg consensus, FactSet, and individual analyst reports as of early March 2026. Targets represent sell-side estimates and are inherently uncertain.

Technology Comparison: What Each Platform Can and Cannot Do

Understanding the molecular differences between these three technologies is essential for evaluating each company's long-term potential.

Capability	CRISPR-Cas9 (Intellia)	Base Editing (Beam)	Prime Editing (Prime Medicine)
Mechanism	Double-strand DNA break	Chemical base conversion (no DSB)	Reverse transcription of new sequence (no DSB)
Edit Types	Gene knockout, large deletions, gene insertion (with template)	4 transition point mutations (C-to-T, A-to-G, and complements)	All 12 point mutations, small insertions, small deletions
% of ClinVar Mutations Addressable	~10% (knockout strategy) to ~40% (with HDR)	~30%	~89%
Double-Strand Breaks	Yes	No	No
Off-Target Risk	Moderate (DSB-dependent)	Lower (no DSB)	Lowest (nick-based)
Delivery Complexity	Moderate (smaller payload)	Moderate	Higher (larger construct)
Editing Efficiency (in vivo)	High (proven in trials)	Moderate-high (emerging data)	Lower (improving)
Clinical Validation	Phase 3 complete	Phase 1/2 (BLA-track)	Phase 1/2
Maturity	Most mature	Intermediate	Earliest

The key insight: these technologies are not direct competitors for the same mutations. They are complementary tools, each best suited for different clinical applications. CRISPR-Cas9 excels at gene knockout. Base editing excels at correcting specific point mutations cleanly. Prime editing can theoretically address the broadest range of genetic changes but needs to prove delivery and efficiency at therapeutic scale.

Risk Factors to Consider

Shared Risks Across All Three

• Regulatory uncertainty: No in vivo gene editing therapy has been approved. The FDA's framework for evaluating permanent, irreversible genomic changes is still evolving.
• Biotech funding environment: Higher interest rates and risk-averse capital markets have compressed valuations across clinical-stage biotech. A prolonged downturn could force dilutive raises.
• Competitive landscape: Large pharma (Roche, Novartis, Lilly) and established biotech (Ionis, Alnylam) are developing competing approaches — including siRNA, antisense, and antibody-based therapies — for many of the same diseases.
• Long-term safety unknowns: Gene editing is permanent. Any late-emerging safety signal (oncogenicity, immune response, off-target edits in unintended tissues) could affect the entire sector.
• Manufacturing and delivery: Scalable GMP manufacturing of LNPs loaded with editing components remains a technical and commercial challenge.

Company-Specific Risks

Intellia:

• Heavy dependence on lonvo-z — a CRL (Complete Response Letter) or clinical hold would be devastating
• In vivo CRISPR creates permanent double-strand breaks; long-term genotoxicity data are limited
• ATTR market is increasingly competitive (tafamidis, eplontersen, CRISPR competitors)

Beam:

• BEAM-101 faces established competition in sickle cell disease from Casgevy and Lyfgenia
• Ex vivo manufacturing model limits scalability advantages
• Base editing restricted to transition mutations; cannot address most insertion/deletion mutations

Prime Medicine:

• Earliest clinical stage; no Phase 3 data expected before 2028–2029
• In vivo delivery of prime editors remains the critical technical bottleneck
• No pharma partnerships; entirely self-funded pipeline development
• Pipeline pivot to liver diseases creates execution risk and timeline uncertainty

Which Stock Fits Your Risk Appetite?

Every investor's situation is different, but here is a framework for thinking about these three names across risk profiles.

Conservative Gene Editing Investor: Beam Therapeutics (BEAM)

Beam offers the strongest balance of clinical validation, financial stability, and platform diversification. With $1.1 billion in cash (runway to 2029), two major pharma partnerships (Pfizer and Apellis), and BEAM-101 on a BLA track, Beam has the most de-risked near-term story. The base editing platform avoids double-strand breaks, which may provide a regulatory advantage. The downside: the $2.8 billion market cap means much of this is already priced in. Beam is unlikely to be a 10x return from here, but it offers meaningful upside with lower downside risk than its peers.

Moderate Risk Tolerance: Intellia Therapeutics (NTLA)

Intellia is the classic "catalyst stock" in gene editing. The lonvo-z Phase 3 data are strong, and a BLA filing (expected in 2026) would be the most significant regulatory event in gene editing since Casgevy. At a $1.5 billion market cap — down 93% from its all-time high — Intellia is priced for significant skepticism. If the BLA filing proceeds on schedule and the FDA accepts it, the stock could re-rate significantly. But investors must be comfortable with binary risk: a regulatory delay or CRL would be painful. Intellia is best suited for investors who believe in the in vivo CRISPR thesis and can tolerate volatility around the regulatory timeline.

Aggressive / Venture-Style Risk: Prime Medicine (PRME)

Prime Medicine is the most speculative of the three — and the one with the most asymmetric upside potential. At a $600 million market cap, the stock is priced as if prime editing might not work in humans. The NEJM-published 83% correction data suggest otherwise. If Prime Medicine can demonstrate even moderate in vivo editing efficiency in its liver disease programs, the re-rating potential is enormous — the theoretical addressable market for prime editing dwarfs that of base editing or CRISPR knockout. But this is a 3–5 year thesis, not a 12-month trade. Prime Medicine is best suited for investors comfortable with early-stage biotech risk who are building a long-term position in what could be the most transformative editing technology.

Catalysts to Watch in 2026–2027

Intellia

• Lonvo-z BLA filing (expected H2 2026) — the single biggest catalyst in next-gen gene editing
• NTLA-2002 Phase 2 data update (HAE program) — H1 2026
• FDA Advisory Committee meeting for lonvo-z — likely H1 2027 if BLA is accepted
• Regeneron pipeline disclosure — updates on collaboration programs

Beam

• BEAM-101 BLA filing preparation — regulatory interactions and CMC readiness throughout 2026
• BEAM-302 Phase 1 data (AATD, in vivo liver program) — H2 2026
• Apellis collaboration first IND — expected 2026
• Multiplex CAR-T program update — preclinical/IND-enabling data

Prime Medicine

• PM359 Phase 1/2 interim data (CDD) — H1 2026
• Liver disease program IND filing(s) — H2 2026 or early 2027
• Potential pharma partnership announcement — could significantly de-risk the stock
• Updated in vivo prime editing efficiency data — key to the long-term thesis

The Bigger Picture: A Maturing Sector

The gene editing investment landscape in 2026 looks very different from the speculative frenzy of 2020–2021, when CRISPR stocks traded at peak hype valuations disconnected from clinical reality. Today, valuations reflect real clinical data, real regulatory timelines, and real commercial questions. That is actually good news for disciplined investors: the stocks are cheaper, the data are better, and the near-term catalysts are more clearly defined.

The three companies in this comparison represent the leading edge of three distinct technological generations. Intellia is the furthest along clinically with the most established technology. Beam occupies the middle ground — clinically advanced with a potentially superior safety profile. Prime Medicine is the earliest but holds the most expansive long-term vision.

It is entirely possible — even likely — that all three technologies find their place in the clinic, targeting different diseases and different mutation types. This is not a winner-take-all market. DNA is complex, human genetics are diverse, and the 7,000+ known genetic diseases will require multiple editing approaches to address.

For investors willing to do the work to understand the science, the gene editing sector in 2026 offers something rare: transformative technology at historically discounted valuations, with definitive clinical catalysts on the near-term horizon.

Sources & Further Reading

• Intellia Therapeutics 2025 10-K Filing — SEC EDGAR, financial data and pipeline overview
• Beam Therapeutics Investor Presentation, January 2026 — Pipeline updates and partnership details
• Prime Medicine PM359 Publication — Arbab, M. et al. "Prime editing correction of CDKL5 deficiency disorder in patient-derived cells." New England Journal of Medicine (2025).
• Liu, D.R. et al. "Search-and-replace genome editing without double-strand breaks or donor DNA." Nature 576, 149–157 (2019). — Original prime editing publication.
• Rees, H.A. & Liu, D.R. "Base editing: precision chemistry on the genome and transcriptome of living cells." Nature Reviews Molecular Cell Biology (2018). — Comprehensive base editing review.
• Gillmore, J.D. et al. "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis." New England Journal of Medicine (2021). — Landmark Intellia in vivo editing data.
• Beam Therapeutics and Apellis Pharmaceuticals Collaboration Announcement — Partnership valued at up to $500M (2025).
• Jefferies NTLA Research Note, February 2026 — Michael Yee, analyst perspective on lonvo-z BLA.
• Citi BEAM Initiation of Coverage — Mohit Bansal, base editing clinical thesis.
• Cowen PRME Initiation Report, January 2026 — Tyler Van Buren, Prime Medicine risk-reward framework.
• ClinVar Database — NCBI, reference for pathogenic variant statistics.
• FDA Gene Therapy Guidance Documents — Regulatory framework for gene editing therapies.

Last updated: March 2026.